Bacterial infections in lung transplantation

Area of Science:

• Infectious diseases in solid organ transplantation
• Pulmonary medicine
• Transplant immunology

Background:

• Lung transplantation survival rates are lower than other solid organ transplants (SOT), largely due to infection and rejection complications.
• Bacterial infections (BI) are the most common infectious complications in lung transplant recipients (LTRs), contributing to morbidity, mortality, allograft loss, and chronic lung allograft dysfunction (CLAD).
• A diverse range of pathogens, including nosocomial and multidrug-resistant (MDR) organisms, can cause infections in LTRs, with pneumonia and intrathoracic infections being predominant.

Purpose of the Study:

• To review the epidemiology, risk factors, and management strategies for bacterial infections in lung transplant recipients.
• To highlight the challenges posed by antibiotic resistance and explore emerging therapeutic approaches.
• To emphasize the importance of surveillance, early diagnosis, and preventative measures in improving outcomes for LTRs.

Main Methods:

• Review of current literature on bacterial infections in lung transplantation.
• Analysis of risk factors, including anatomical, immunological, microbial, and genetic elements.
• Discussion of diagnostic methods, antimicrobial therapies, and infection prevention strategies.

Main Results:

• Bacterial infections are a primary driver of poor outcomes in lung transplantation, directly causing mortality and indirectly leading to rejection and CLAD.
• Risk factors for BI are multifactorial, involving donor and recipient factors, airway alterations, and impaired immunity.
• Emerging molecular techniques offer new insights into the lung microbiome and its role in infection and allograft dysfunction.

Conclusions:

• Effective management of bacterial infections in LTRs requires a comprehensive approach, including surveillance, prompt diagnosis, and aggressive antimicrobial therapy.
• Addressing antibiotic resistance and exploring novel treatments like bacteriophage therapy are critical for future success.
• Preventative strategies, such as prophylaxis, vaccination, and stringent infection control, are essential components of post-transplant care.